<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37051070</PMID><DateRevised><Year>2023</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2633-6960</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Oxford open immunology</Title><ISOAbbreviation>Oxf Open Immunol</ISOAbbreviation></Journal><ArticleTitle>Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2.</ArticleTitle><Pagination><StartPage>iqad001</StartPage><MedlinePgn>iqad001</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">iqad001</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/oxfimm/iqad001</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes lethal coronavirus disease (COVID-19). SARS-CoV-2 has been the chief source of threat to public health and safety from 2019 to the present. SARS-CoV-2 caused a sudden and significant rise in hospitalization due to respiratory issues and pneumonia. We are consistently uncovering new information about SARS-CoV-2, and yet so much is to explore to implement efficient interventions to combat the emergent variants and spread of the ongoing pandemic. Information regarding the existing COVID-19 pandemic is streamlining continuously. However, clinical symptoms of SARS-CoV-2 infections spanning from asymptomatic infection to severe death-instigating disease remain consistent with preliminary reports. In this review, we have briefly introduced highlights of the COVID-19 pandemic and features of SARS-CoV-2. We have focused on current knowledge of innate and adaptive immune responses during SARS-CoV-2 infections and persisting clinical features of recovered patients. Furthermore, we have discussed how these immune responses are not tightly regulated and imbalance can direct the latter phases of COVID-19, long-COVID symptoms, and cause detrimental immunopathogenesis. COVID-19 vaccines are also discussed in detail to describe the efforts going around the world to control and prevent the infection. Overall, we have summarized the current knowledge on the immunology of SARS-CoV-2 infection and the utilization of that knowledge in the development of a suitable COVID-19 therapeutics and vaccines.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Negi</LastName><ForeName>Kriti</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Immunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Meetu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Jamia Hamdard University, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pahuja</LastName><ForeName>Isha</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Immunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine, Jamia Hamdard University, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhardwaj</LastName><ForeName>Bhavya</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Immunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rawat</LastName><ForeName>Mansi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Immunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhaskar</LastName><ForeName>Ashima</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dwivedi</LastName><ForeName>Ved Prakash</ForeName><Initials>VP</Initials><Identifier Source="ORCID">0000-0003-4321-2567</Identifier><AffiliationInfo><Affiliation>Immunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oxf Open Immunol</MedlineTA><NlmUniqueID>101770669</NlmUniqueID><ISSNLinking>2633-6960</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>1</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37051070</ArticleId><ArticleId IdType="pmc">PMC9985161</ArticleId><ArticleId IdType="doi">10.1093/oxfimm/iqad001</ArticleId><ArticleId IdType="pii">iqad001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hu B, Guo H, Zhou P. et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19:141&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralinski LE, Menachery VD.. Return of the coronavirus: 2019-nCoV. Viruses 2020;12(2):135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7077245</ArticleId><ArticleId IdType="pubmed">31991541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC. et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020:324:782&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothe C, et al.Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. New Engl J Med 2020;382:970&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7120970</ArticleId><ArticleId IdType="pubmed">32003551</ArticleId></ArticleIdList></Reference><Reference><Citation>
Chippa V, Aleem A, Anjum F. Post-acute coronavirus (COVID-19) syndrome. 2021. https://www.globenewswire.com/news-release/2020/07/20/2064154/0/en/Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.html.</Citation><ArticleIdList><ArticleId IdType="pubmed">34033370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang X-L, Wang X-G. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270&#x2013;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Liao X, Qian S. et al. Community transmission of severe acute respiratory syndrome coronavirus 2, Shenzhen, China, 2020. Emerg Infect Dis 2020;26:1320&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7258448</ArticleId><ArticleId IdType="pubmed">32125269</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doremalen N, Bushmaker T, Morris DH. et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382:1564&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121658</ArticleId><ArticleId IdType="pubmed">32182409</ArticleId></ArticleIdList></Reference><Reference><Citation>Fears AC, Klimstra WB, Duprex P. et al. Persistence of severe acute respiratory syndrome coronavirus 2 in aerosol suspensions. Emerg Infect Dis 2020;(9):2168&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454081</ArticleId><ArticleId IdType="pubmed">32568661</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y, Zhang D, Yang P. et al. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis 2020;20:411&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128099</ArticleId><ArticleId IdType="pubmed">32105638</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S, Fan J, Yu F. et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ 2020;369:m1443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190077</ArticleId><ArticleId IdType="pubmed">32317267</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Xu Y, Gao R. et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020;323:1843&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066521</ArticleId><ArticleId IdType="pubmed">32159775</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Guo C, Tang L. et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020;5:434&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158584</ArticleId><ArticleId IdType="pubmed">32199469</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J-G, Li D-Y, Wang C-F. et al. Positive RT-PCR in urine from an asymptomatic patient with novel coronavirus 2019 infection: a case report. Infect Dis (Lond) 2020;52:571&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">32420777</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong SWX, Tan YK, Chia PY. et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA 2020;323:1610&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7057172</ArticleId><ArticleId IdType="pubmed">32129805</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M, Tate M, Lloyd O. et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe 2021;2:e13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo L, Masters PS.. The small envelope protein E is not essential for murine coronavirus replication. J Virol 2003;77:4597&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC152126</ArticleId><ArticleId IdType="pubmed">12663766</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortego J, Ceriani JE, Pati&#xf1;o C. et al. Absence of E protein arrests transmissible gastroenteritis coronavirus maturation in the secretory pathway. Virology 2007;368:296&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7103363</ArticleId><ArticleId IdType="pubmed">17692883</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruch TR, Machamer CE.. The Coronavirus E Protein: Assembly and Beyond. Viruses 2012;4:363&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3347032</ArticleId><ArticleId IdType="pubmed">22590676</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Z, Dominguez SR, Holmes KV.. Role of the spike glycoprotein of human Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in virus entry and syncytia formation. PLOS ONE 2013;8:e76469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3789674</ArticleId><ArticleId IdType="pubmed">24098509</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehr AR, Perlman S.. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369385</ArticleId><ArticleId IdType="pubmed">25720466</ArticleId></ArticleIdList></Reference><Reference><Citation>de Haan CAM, Rottier PJM.. Molecular interactions in the assembly of coronaviruses. Adv Virus Res 2005;64:165&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112327</ArticleId><ArticleId IdType="pubmed">16139595</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride R, Van Zyl M, Fielding BC.. The coronavirus nucleocapsid is a multifunctional protein. Viruses 2014;6:2991&#x2013;3018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4147684</ArticleId><ArticleId IdType="pubmed">25105276</ArticleId></ArticleIdList></Reference><Reference><Citation>Tooze J, Tooze S, Warren G.. Replication of coronavirus MHV-A59 in sac-cells: determination of the first site of budding of progeny virions. Eur J Cell Biol 1984;33:281&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">6325194</ArticleId></ArticleIdList></Reference><Reference><Citation>Klumperman J, Locker JK, Meijer A. et al. Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding. J Virol 1994;68:6523&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237073</ArticleId><ArticleId IdType="pubmed">8083990</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoeman D, Fielding BC.. Coronavirus envelope protein: current knowledge. Virol J 2019;16:69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6537279</ArticleId><ArticleId IdType="pubmed">31133031</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerbeck JW, Machamer CE.. The infectious bronchitis coronavirus envelope protein alters Golgi pH to protect the spike protein and promote the release of infectious virus. J Virol 2019;93(11):e00015&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6532078</ArticleId><ArticleId IdType="pubmed">30867314</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuman BW, Kiss G, Kunding AH. et al. A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol 2011;174:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486061</ArticleId><ArticleId IdType="pubmed">21130884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai MM, Cavanagh D.. The molecular biology of coronaviruses. Adv Virus Res 1997;48:1&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7130985</ArticleId><ArticleId IdType="pubmed">9233431</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen VP, Hogue BG.. Protein interactions during coronavirus assembly. J Virol 1997;71:9278&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230230</ArticleId><ArticleId IdType="pubmed">9371586</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan K, Maeda A, Maeda J. et al. Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells. J Virol 2000;74:8127&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112346</ArticleId><ArticleId IdType="pubmed">10933723</ArticleId></ArticleIdList></Reference><Reference><Citation>Escors D, Ortego J, Laude H. et al. The Membrane M protein carboxy terminus binds to transmissible gastroenteritis coronavirus core and contributes to core stability. J Virol 2001;75:1312&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114037</ArticleId><ArticleId IdType="pubmed">11152504</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudoux P, Carrat C, Besnardeau L. et al. Coronavirus pseudoparticles formed with recombinant M and E proteins induce alpha interferon synthesis by leukocytes. J Virol 1998;72:8636&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110275</ArticleId><ArticleId IdType="pubmed">9765403</ArticleId></ArticleIdList></Reference><Reference><Citation>Corse E, Machamer CE.. Infectious bronchitis virus E protein is targeted to the golgi complex and directs release of virus-like particles. J Virol 2000;74:4319&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC111949</ArticleId><ArticleId IdType="pubmed">10756047</ArticleId></ArticleIdList></Reference><Reference><Citation>Corse E, Machamer CE.. The cytoplasmic tails of infectious bronchitis virus E and M proteins mediate their interaction. Virology 2003;312:25&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127533</ArticleId><ArticleId IdType="pubmed">12890618</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatagopalan P, Daskalova SM, Lopez LA. et al. Coronavirus envelope (E) protein remains at the site of assembly. Virology 2015;478:75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550588</ArticleId><ArticleId IdType="pubmed">25726972</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieto-Torres JL, Dediego ML, Alvarez E. et al. Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein. Virology 2011;415:69&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4726981</ArticleId><ArticleId IdType="pubmed">21524776</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis KM, Yount B, Baric RS.. Heterologous gene expression from transmissible gastroenteritis virus replicon particles. J Virol 2002;76:1422&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC135785</ArticleId><ArticleId IdType="pubmed">11773416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortego J, Escors D, Laude H. et al. Generation of a replication-competent, propagation-deficient virus vector based on the transmissible gastroenteritis coronavirus genome. J Virol 2002;76:11518&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC136772</ArticleId><ArticleId IdType="pubmed">12388713</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Moore MJ, Vasilieva N. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095016</ArticleId><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Letko M, Marzi A, Munster V.. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020;5:562&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095430</ArticleId><ArticleId IdType="pubmed">32094589</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls AC, Park Y-J, Tortorici MA. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281&#x2013;292.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Belouzard S, Millet JK, Licitra BN. et al. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 2012;4:1011&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3397359</ArticleId><ArticleId IdType="pubmed">22816037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou X, Liu Y, Lei X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 2020;11:1620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7100515</ArticleId><ArticleId IdType="pubmed">32221306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271&#x2013;280.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Wen Z, Zhong G. et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 2020;368:1016&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164390</ArticleId><ArticleId IdType="pubmed">32269068</ArticleId></ArticleIdList></Reference><Reference><Citation>Gantt PA, McDonough PG.. Adolescent dysmenorrhea. Pediatr Clin North Am 1981;28:389&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">7243369</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G.. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med 2020;252:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206933</ArticleId><ArticleId IdType="pubmed">32356627</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Shi L, Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N, Hui D, Wu A. et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId></ArticleIdList></Reference><Reference><Citation>Assiri A, Al-Tawfiq JA, Al-Rabeeah AA. et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013;13:752&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7185445</ArticleId><ArticleId IdType="pubmed">23891402</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauer SA, Grantz KH, Bi Q. et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020;172:577&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7081172</ArticleId><ArticleId IdType="pubmed">32150748</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Guan X, Wu P. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121484</ArticleId><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM.. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a Report of 72&#x202f;314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes EK, Zambrano LD, Anderson KN. et al. Coronavirus disease 2019 case surveillance &#x2014; United States, January 22&#x2013;May 30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:759&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302472</ArticleId><ArticleId IdType="pubmed">32555134</ArticleId></ArticleIdList></Reference><Reference><Citation>Madjid M, Safavi-Naeini P, Solomon SD. et al. Potential effects of coronaviruses on the cardiovascular system: A review. JAMA Cardiol 2020;5:831&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">32219363</ArticleId></ArticleIdList></Reference><Reference><Citation>Paniz-Mondolfi A, Bryce C, Grimes Z. et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol 2020;92:699&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264598</ArticleId><ArticleId IdType="pubmed">32314810</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A, Chen A, Ravindran N. et al. Gastrointestinal and liver manifestations of COVID-19. J Clin Exp Hepatol 2020;10:263&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7212283</ArticleId><ArticleId IdType="pubmed">32405183</ArticleId></ArticleIdList></Reference><Reference><Citation>Su H, Yang M, Wan C. et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 2020;98:219&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194105</ArticleId><ArticleId IdType="pubmed">32327202</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B, Madhavan MV, Jimenez D. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:2950&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L.. Management of post-acute covid-19 in primary care. BMJ. 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol 2021;93:1013&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Yu Y, Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine 2020;8:475&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai T, Yang Z, Hou H. et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology 2020;296:E32&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233399</ArticleId><ArticleId IdType="pubmed">32101510</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman VM, Landt O, Kaiser M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;(3):2000045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>Winichakoon P, Chaiwarith R, Liwsrisakun C. et al. Negative nasopharyngeal and oropharyngeal swabs do not rule out COVID-19. J Clin Microbiol 2020;58(5):e00297&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7180262</ArticleId><ArticleId IdType="pubmed">32102856</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf6;lfel R, Corman VM, Guggemos W. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020;581:465&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson J, Whiting PF, Brush JE.. Interpreting a covid-19 test result. BMJ 2020;369:m1808.</Citation><ArticleIdList><ArticleId IdType="pubmed">32398230</ArticleId></ArticleIdList></Reference><Reference><Citation>Notomi T, Okayama H, Masubuchi H. et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res 2000;28:E63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102748</ArticleId><ArticleId IdType="pubmed">10871386</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellner MJ, Koob JG, Gootenberg JS. et al. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc 2019;14:2986&#x2013;3012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6956564</ArticleId><ArticleId IdType="pubmed">31548639</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerman CM, Myhrvold C, Thakku SG. et al. Massively multiplexed nucleic acid detection with Cas13. Nature 2020;582:277&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332423</ArticleId><ArticleId IdType="pubmed">32349121</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JS, Ma E, Harrington LB. et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science 2018;360:436&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6628903</ArticleId><ArticleId IdType="pubmed">29449511</ArticleId></ArticleIdList></Reference><Reference><Citation>Broughton JP, Deng X, Yu G. et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol 2020;38:870&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9107629</ArticleId><ArticleId IdType="pubmed">32300245</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh KA, Jordan K, Clyne B. et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect 2020;81:357&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323671</ArticleId><ArticleId IdType="pubmed">32615199</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina MJ, Parker R, Larremore DB.. Rethinking Covid-19 test sensitivity - a strategy for containment. N Engl J Med 2020;383:e120.</Citation><ArticleIdList><ArticleId IdType="pubmed">32997903</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju B., Zhang Q., Ge J.. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 2020;584:115&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">32454513</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni L, Ye F, Cheng ML. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 2020;16;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196424</ArticleId><ArticleId IdType="pubmed">32413330</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury MT, Sarkar A, Paul SK. et al. A case study on strategies to deal with the impacts of COVID-19 pandemic in the food and beverage industry. J Oper Manag Res 2022;15:166&#x2013;78.</Citation></Reference><Reference><Citation>Fitzgerald KA, Kagan JC.. Toll-like receptors and the control of immunity. Cell 2020;180:1044&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9358771</ArticleId><ArticleId IdType="pubmed">32164908</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D, Geng T, Harrison AG. et al. Differential roles of RIG-I-like receptors in SARS-CoV-2 infection. Immunology 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8421188</ArticleId><ArticleId IdType="pubmed">34488908</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanmohammadi S, Rezaei N.. Role of Toll&#x2010;like receptors in the pathogenesis of COVID&#x2010;19. J Med Virol 2021;93:2735&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014260</ArticleId><ArticleId IdType="pubmed">33506952</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the &#x201c;culprit lesion&#x201d; of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine X 2020;2:100029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224649</ArticleId><ArticleId IdType="pubmed">32421092</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif D, Hammi I, Kihel A. et al. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb Pathog 2021;153:104799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7889464</ArticleId><ArticleId IdType="pubmed">33609650</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahid A et al. Molecular and structural basis of DNA sensors in antiviral innate immunity. Front Immunol 2020;11:613039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734173</ArticleId><ArticleId IdType="pubmed">33329609</ArticleId></ArticleIdList></Reference><Reference><Citation>Domizio JD et al. "The cGAS&#x2013;STING pathway drives type I IFN immunopathology in COVID-19." Nature 2022;603:145&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891013</ArticleId><ArticleId IdType="pubmed">35045565</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Li B, Ning B.. The comparative immunological characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 coronavirus infections. Front Immunol 2020;11:2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7457039</ArticleId><ArticleId IdType="pubmed">32922406</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Dong X, Ma R. et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun 2020;11:3810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392898</ArticleId><ArticleId IdType="pubmed">32733001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowery SA, Sariol A, Perlman S.. Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. Cell Host Microbe 2021;29:1052&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126603</ArticleId><ArticleId IdType="pubmed">34022154</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah VK, Firmal P, Alam A. et al. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front Immunol 2020;11:1949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426442</ArticleId><ArticleId IdType="pubmed">32849654</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra M, Tian R, Zhang C. et al. Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes. Sci Rep 2021;11:3455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875990</ArticleId><ArticleId IdType="pubmed">33568776</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L, He Y, Zhou Y. et al. The spike protein of SARS-CoV &#x2014; a target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7:226&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750777</ArticleId><ArticleId IdType="pubmed">19198616</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou H, Wang T, Zhang B. et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunol 2020;9(5):e01136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202656</ArticleId><ArticleId IdType="pubmed">32382418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley SF, O&#x2019;Donnell D, Stoesser NE. et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med 2021;384:533&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781098</ArticleId><ArticleId IdType="pubmed">33369366</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor A, Foo S-S, Bruzzone R. et al. Fc receptors in antibody-dependent enhancement of viral infections. Immunol Rev 2015;268:340&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165974</ArticleId><ArticleId IdType="pubmed">26497532</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W. et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun 2021;12:5417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan RK, Kashour T, Hamid Q. et al. Unraveling the mystery surrounding post-acute sequelae of COVID-19. Front Immunol 2021;12:686029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8278217</ArticleId><ArticleId IdType="pubmed">34276671</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Liu Y, Xiang P. et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 2020;18:206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237880</ArticleId><ArticleId IdType="pubmed">32434518</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Martin JC.. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020;20:355&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201395</ArticleId><ArticleId IdType="pubmed">32376901</ArticleId></ArticleIdList></Reference><Reference><Citation>Martonik D, Parfieniuk-Kowerda A, Rogalska M. et al. The Role of Th17 Response in COVID-19. Cells 2021;10:1550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8235311</ArticleId><ArticleId IdType="pubmed">34205262</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson JJ, Crooks C, Naja M. et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol 2020;2:e594&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442426</ArticleId><ArticleId IdType="pubmed">32864628</ArticleId></ArticleIdList></Reference><Reference><Citation>Batah SS, Fabro AT.. Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. Respir Med 2021;176:106239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674971</ArticleId><ArticleId IdType="pubmed">33246294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaim S, Chong JH, Sankaranarayanan V. et al. COVID-19 and multiorgan response. Curr Probl Cardiol 2020;45:100618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187881</ArticleId><ArticleId IdType="pubmed">32439197</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi HK, Mehra MR.. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant 2020;39:405&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118652</ArticleId><ArticleId IdType="pubmed">32362390</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisonnasse P, Guedj J, Contreras V.. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature 2020;585(7826):584&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32698191</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren TK, Jordan R, Lo MK. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016;531:381&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5551389</ArticleId><ArticleId IdType="pubmed">26934220</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Cao R, Zhang L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7054408</ArticleId><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM. et al. Remdesivir for the treatment of Covid-19-final report . N Engl J Med 2020;383(19):1813&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H, Peto R, Henao-Restrepo AM. et al. Repurposed antiviral drugs for Covid-19-Interim WHO Solidarity Trial Results. N Engl J Med 2021;174(2):JC17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta Y, Komeno T, Nakamura T.. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 2017;93:449&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5713175</ArticleId><ArticleId IdType="pubmed">28769016</ArticleId></ArticleIdList></Reference><Reference><Citation>Omura S, Crump A.. Ivermectin: panacea for resource-poor communities? Trends Parasitol 2014;30:445&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">25130507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircik LH, Del Rosso JQ, Layton AM. et al. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol 2016;15:325&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">26954318</ArticleId></ArticleIdList></Reference><Reference><Citation>Jans DA, Martin AJ, Wagstaff KM.. Inhibitors of nuclear transport. Curr Opin Cell Biol 2019;58:50&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">30826604</ArticleId></ArticleIdList></Reference><Reference><Citation>Caly L, Druce JD, Catton MG. et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020;178:104787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7129059</ArticleId><ArticleId IdType="pubmed">32251768</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaccour C, Hammann F, Ram&#xf3;n-Garc&#xed;a S. et al. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop Med Hyg 2020;102:1156&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7253113</ArticleId><ArticleId IdType="pubmed">32314704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M-S, Chen W-J, Chen H-Y. et al. Neutralizing antibody response and SARS severity. Emerg Infect Dis 2005;11:1730&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367364</ArticleId><ArticleId IdType="pubmed">16318725</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Y, Shang J, Graham R. et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94(7):e00127&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7081895</ArticleId><ArticleId IdType="pubmed">31996437</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R, Zhao X, Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, Wang A, Liu M. et al. Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications. medRxiv 2020.03.30.20047365.</Citation></Reference><Reference><Citation>Chen X, Li R, Pan Z. et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol 2020;17:647&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167496</ArticleId><ArticleId IdType="pubmed">32313207</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Wang F, Shen C. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 2020;368:1274&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7223722</ArticleId><ArticleId IdType="pubmed">32404477</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen J, Baum A, Pascal KE. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 2020;369:1010&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299284</ArticleId><ArticleId IdType="pubmed">32540901</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A, Fulton BO, Wloga E. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 2020;369:1014&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb RL, Nirula A, Chen P. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 2021;325:632&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821080</ArticleId><ArticleId IdType="pubmed">33475701</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich DM, Sivapalasingam S, Norton T, et al.Trial investigators: REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021;384:238&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781102</ArticleId><ArticleId IdType="pubmed">33332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CK, Lam CWK, Wu AKL. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004;136:95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1808997</ArticleId><ArticleId IdType="pubmed">15030519</ArticleId></ArticleIdList></Reference><Reference><Citation>Faure E, Poissy J, Goffard A. et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One 2014;9:e88716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3925152</ArticleId><ArticleId IdType="pubmed">24551142</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockman LJ, Bellamy R, Garner P.. SARS: systematic review of treatment effects. PLoS Med 2006;3:e343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1564166</ArticleId><ArticleId IdType="pubmed">16968120</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi YM, Mandourah Y, Al-Hameed F. et al. Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med 2018;197:757&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">29161116</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeronimo CMP, Farias MEL, Val FFA. et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. Clin Infect Dis 2021;72:e373&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454320</ArticleId><ArticleId IdType="pubmed">32785710</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group, Horby P, Lim WS. et al.Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Li W, Jin Y. et al. Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: A Retrospective Cohort Study. Infect Dis Ther 2020;9:823&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7467137</ArticleId><ArticleId IdType="pubmed">32880102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung IFN, To KKW, Lee C-K. et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013;144:464&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">23450336</ArticleId></ArticleIdList></Reference><Reference><Citation>Soo YOY, Cheng Y, Wong R. et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004;10:676&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7129386</ArticleId><ArticleId IdType="pubmed">15214887</ArticleId></ArticleIdList></Reference><Reference><Citation>Mair-Jenkins J, Saavedra-Campos M, Baillie JK. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015;211:80&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4264590</ArticleId><ArticleId IdType="pubmed">25030060</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Fontanet A, Zhang P-H. et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis 2006;193:792&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7109932</ArticleId><ArticleId IdType="pubmed">16479513</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Guo X, Xin Q. et al. Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. Clin Infect Dis 2020;71:2688&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314147</ArticleId><ArticleId IdType="pubmed">32497196</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner MJ, Carter RE, Senefeld JW. et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med 2021;384:1015&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821984</ArticleId><ArticleId IdType="pubmed">33523609</ArticleId></ArticleIdList></Reference><Reference><Citation>The RECOVERY Collaborative Group, Horby PW, Estcourt L. et al.Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397(10289):2049&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8121538</ArticleId><ArticleId IdType="pubmed">34000257</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R, Fehr AR, Vijay R. et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 2016;19:181&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752723</ArticleId><ArticleId IdType="pubmed">26867177</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R, Fehr AR, Zheng J. et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest 2019;129:3625&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6715373</ArticleId><ArticleId IdType="pubmed">31355779</ArticleId></ArticleIdList></Reference><Reference><Citation>Omrani AS, Saad MM, Baig K. et al. Ribavirin and interferon alfa-2a for severe Middle East Respiratory Syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 2014;14:1090&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7106357</ArticleId><ArticleId IdType="pubmed">25278221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu CM, Cheng VCC, Hung IFN. et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1746980</ArticleId><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalhoub S, Farahat F, Al-Jiffri A. et al. IFN-&#x3b1;2a or IFN-&#x3b2;1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 2015;70:2129&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202429</ArticleId><ArticleId IdType="pubmed">25900158</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantlo E, Bukreyeva N, Maruyama J. et al. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res 2020;179:104811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188648</ArticleId><ArticleId IdType="pubmed">32360182</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al.Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 .Cell 2020;5:1036&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, Yatim N, Barnabei L. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020;369:718&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Bastard P, Liu Z. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020;370(6515):eabd4570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Hearson G. Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients. nrruv1 2020.</Citation></Reference><Reference><Citation>Hung IF-N, Lung K-C, Tso EY-K. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395:1695&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211500</ArticleId><ArticleId IdType="pubmed">32401715</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Chen V, Shannon CP. et al. Interferon-&#x3b1;2b treatment for COVID-19. Front Immunol 2020;11:1061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242746</ArticleId><ArticleId IdType="pubmed">32574262</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal P, Choi JJ, Pinheiro LC. et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020;382:2372&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182018</ArticleId><ArticleId IdType="pubmed">32302078</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020;584:463&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Q, Wang B, Mao J.. The pathogenesis and treatment of the &#x2032;Cytokine Storm&#x2019; in COVID-19. J Infect 2020;80:607&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194613</ArticleId><ArticleId IdType="pubmed">32283152</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakoory B, Carcillo JA, Chatham WW. et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a Prior Phase III Trial. Crit Care Med 2016;44:275&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378312</ArticleId><ArticleId IdType="pubmed">26584195</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteagudo LA, Boothby A, Gertner E.. Continuous intravenous anakinra infusion to calm the cytokine storm in Macrophage Activation Syndrome. ACR Open Rheumatol 2020;2:276&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7231518</ArticleId><ArticleId IdType="pubmed">32267081</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli G, De Luca G, Campochiaro C. et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020;2:e325&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252085</ArticleId><ArticleId IdType="pubmed">32501454</ArticleId></ArticleIdList></Reference><Reference><Citation>CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med 2021;9:295&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7825875</ArticleId><ArticleId IdType="pubmed">33493450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">19494217</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020;395:507&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Liu HG, Liu W. et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia ]. Zhonghua Jie He He Hu Xi Za Zhi 2020;43:E005.</Citation><ArticleIdList><ArticleId IdType="pubmed">32026671</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathan N, Hemingway CA, Alizadeh AA. et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 2004;363:203&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14738793</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Han M, Li T. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020;117:10970&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7245089</ArticleId><ArticleId IdType="pubmed">32350134</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone JH, Frigault MJ, Serling-Boyd NJ. et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020;383:2333&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7646626</ArticleId><ArticleId IdType="pubmed">33085857</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Mariette X, Tharaux P-L. et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med 2021;181:32&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577198</ArticleId><ArticleId IdType="pubmed">33080017</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group, Horby PW, Pessoa-Amorim G. et al.Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): Preliminary results of a randomised, controlled, open-label, platform trial. Lancet 2021;397(10285):1637&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>REMAP-CAP Investigators, Gordon AC, Mouncey PR. et al.Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 2021;384:1491&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman MB. Pharmaceutical approval update . P T 2017;42:562&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5565128</ArticleId><ArticleId IdType="pubmed">28890641</ArticleId></ArticleIdList></Reference><Reference><Citation>Huizinga TWJ, Fleischmann RM, Jasson M. et al. Sarilumab, a fully human monoclonal antibody against IL-6R&#x3b1; in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 2014;73:1626&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145418</ArticleId><ArticleId IdType="pubmed">24297381</ArticleId></ArticleIdList></Reference><Reference><Citation>Lescure F-X, Honda H, Fowler RA. et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2021;9:522&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078879</ArticleId><ArticleId IdType="pubmed">33676590</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinti I, Mitrevski M.. Modulatory effects of antibody replacement therapy to innate and adaptive immune cells. Front Immunol 2017;8:697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5472665</ArticleId><ArticleId IdType="pubmed">28670314</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimering MB. Severe COVID-19 pneumonia is associated with increased plasma immunoglobulin G agonist autoantibodies targeting the 5-hydroxytryptamine 2a receptor. Endocrinol Diabetes Metab J 2021;5:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7931266</ArticleId><ArticleId IdType="pubmed">33680365</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N, Hogan MJ, Porter FW. et al. mRNA vaccines&#x2014;a new era in vaccinology. Nat Rev Drug Discovery 2018;17:261&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Kream RM, Stefano GB.. Long-term respiratory and neurological sequelae of COVID-19. Med Sci Monit 2020;26:e928996-1&#x2013;e928996-10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7643287</ArticleId><ArticleId IdType="pubmed">33177481</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulligan MJ, Lyke KE, Kitchin N. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020;586:589&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">32785213</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov DY, Dolzhikova IV, Zubkova OV. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020;396:887&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7471804</ArticleId><ArticleId IdType="pubmed">32896291</ArticleId></ArticleIdList></Reference><Reference><Citation>George PM, Barratt SL, Condliffe R, et al.Respiratory follow-up of patients with COVID-19 pneumonia. Thorax 2020;751:1009&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">32839287</ArticleId></ArticleIdList></Reference><Reference><Citation>Roper RL, Rehm KE.. SARS vaccines: where are we? Expert Rev Vaccines 2009;87:887&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105754</ArticleId><ArticleId IdType="pubmed">19538115</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawat K, Kumari P, Saha L.. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol 2021;892:173751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7685956</ArticleId><ArticleId IdType="pubmed">33245898</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>